Lyphe

Lyphe, founded in 2019, is a pioneering player in the UK and Channel Islands’ medical cannabis sector. Their slogan, "Specialists in medical cannabis treatment in the UK and Channel Islands. Your patient-first path to natural wellness," underscores their commitment to enhancing patient care through personalized cannabis-based treatments.

Lyphe focuses on increasing awareness and acceptance of medical cannabis as a viable treatment for a range of conditions, from chronic pain to neurological and complex disorders. They emphasize delivering prescriptions directly to patients and provide ongoing support and necessary adjustments.

Recently, Lyphe attracted attention from industry players, culminating in a significant acquisition investment by Tilray on 01 April 2026. This strategic move positions the company for expanded growth in the competitive medical cannabis market, leveraging their existing infrastructure and expertise to better serve the patient community while potentially augmenting investor returns.